Here's How Lilly's Non-Obesity Drugs are Contributing to Sales Growth

Eli Lilly's Q1 sales growth was primarily fueled by its GLP-1 drugs, Mounjaro and Zepbound, which accounted for 48% of total sales; however, non-obesity products like oncology drug Verzenio (up 10% YoY) and immunology drug Taltz (up 26% YoY) also contributed significantly, underscoring the company's broader pipeline strength in areas such as oncology, immunology, and neuroscience. This diversification strategy mirrors a wider trend among pharmaceutical giants like AbbVie and Merck, who are also expanding beyond their core revenue drivers. While investor focus remains on GLP-1 sequential growth, LLY shares trade at a premium valuation of 29.45x forward P/E, leading to a Zacks Rank #4 (Sell).

Analysis

Eli Lilly's revenue growth dynamic is twofold: while the GLP-1 drugs Mounjaro and Zepbound are the primary drivers, accounting for 48% of first-quarter sales, the company's non-obesity portfolio demonstrates significant strength and diversification. Key products in oncology and immunology, Verzenio and Taltz, delivered substantial year-over-year sales growth of 10% and 26% respectively, contributing a combined 15% of total Q1 revenue. This strategy of broadening therapeutic reach beyond flagship drugs mirrors moves by peers like AbbVie and Merck, indicating an industry-wide trend to mitigate concentration risk. Despite this diversified growth, investor focus remains intensely on the GL-1 franchise, with model estimates projecting Q2 sales of $4.46 billion for Mounjaro and $3.09 billion for Zepbound. This growth narrative is set against a challenging valuation; LLY trades at a forward P/E of 29.45, nearly double the industry average of 15.04. This premium valuation persists even as 2025 EPS estimates have seen a slight decline in the past 60 days, contributing to the source's Zacks Rank #4 (Sell) rating.

Key Decisions for Investors

• Investors should weigh Eli Lilly's robust growth from its GLP-1 franchise and diversifying portfolio against its premium valuation, which at a 29.45x forward P/E is significantly higher than the industry average.
• The upcoming second-quarter earnings report is a critical catalyst; pay close attention to the sequential growth of Mounjaro and Zepbound, as any failure to meet high expectations could pressure the stock.
• Given the high valuation and the source's 'Sell' rating, consider monitoring the performance of the non-obesity portfolio (Verzenio, Taltz) as a key indicator of the company's long-term, diversified earnings power beyond the current GLP-1 focus.
• For sector-level exposure, it may be prudent to evaluate the relative valuation and diversification progress of peers like AbbVie and Merck, which are also expanding beyond their primary revenue drivers but may present a different risk-reward profile.